Confirmation of the chromosome damaging effects of lamivudine in in vitro human peripheral blood lymphocytes

Environmental and Molecular Mutagenesis

Volumn 49, Issue 4, 2008, Pages 328-333

  Bayram, Süleyman ^a   Topaktaş, Mehmet ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Chromosome aberration; Human peripherol lymphocytes; Lamivudine; Micronucleus; Sister chromatid exchange

Indexed keywords

LAMIVUDINE;

ARTICLE; CELL PROLIFERATION; CHROMOSOME DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICRONUCLEUS TEST; MITOSIS INDEX; PERIPHERAL LYMPHOCYTE; SISTER CHROMATID EXCHANGE;

ADULT; ANTI-HIV AGENTS; CELL PROLIFERATION; CELLS, CULTURED; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; LAMIVUDINE; LYMPHOCYTES; MALE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MITOTIC INDEX; MUTAGENICITY TESTS; REVERSE TRANSCRIPTASE INHIBITORS; SISTER CHROMATID EXCHANGE;

EID: 42949159663     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20393     Document Type: Article

References (35)

1. Albertini RJ, Anderson D, Douglas GR, Hagmar L, Hemminki K, Merlo F, Natarajan AT, Norppa H, Shuker DEG, Tice R, Waters MD, Aitio A. 2000. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res 463:111-172.
2. Bonassi S, Hagmar L, Strömberg U, Montagud AH, Tinnerberg H, Forni A, Heikkilä P, Wanders S, Wilhardt P, Hansteen I-L, Knudsen LE, Norppa H. 2000. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res 60:1619-1625.
3. Bonassi S, Znaor A, Norppa H, Hagmar L, 2004. Chromosomal aberrations and risk of cancer in humans: An epidemiologic perspective. Cytogenet Genome Res 104:376-382.
4. Bonassi S, Ugolini D, Kirsch-Volders M, Strömberg U, Vermeulen R, Tucker JD. 2005. Human population with cytogenetic biomarkers: Review of the literature and future prospectives. Environ Mol Mutagen 45:258-270.
5. Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, Kirsch-Volders M, Zeiger E, Ban S, Barale R, Bigatti MP, Bolognesi C, Cebulska-Wasilewska A, Fabianova E, Fucic A, Hagmar L, Joksic G, Martelli A, Migliore L, Mirkova E, Scarfi MR, Zijno A, Norppa H, Fenech M. 2007. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28:625-631.
6. Carrano AV, Natarajan AT. 1988. Consideration for population monitoring using cytogenetic techniques. Mutat Res 204:379-406.
7. Cassiman JJ, de Clercq E, Jones AS, Walker RT, van Berghe H. 1983. Sister chromatid exchange induced by anti-herpes drugs. Br Med J 283:817-818.
8. Darnowski JW, Goulette FA. 1994. 3′-Azido-3′-deoxythymidine cytotoxicity and metabolism in the human colon tumor cell line HCT-8. Biochem Pharmacol 48:1797-1805.
9. de Clercq E, Cassiman JJ. 1986. Mutagenic potential of anti-herpes agents. Life Sci 38:281-289.
10. Evans HJ. 1984. Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. In: Kilbey BJ, Legator M, Nichols W, Ramel C, Editors. Handbook of Mutagenicity Test Procedures, 2nd ed. Amsterdam: Elsevier Science Publishers, BV. p 405-427.
11. Fenech M, Morley AA. 1985. Measurement of micronuclei in lymphocytes. Mutat Res 147:29-36.
12. Gonzalez CM, Larripa I. 1994. Genotoxicity of azidothymidine (AZT) in in vitro systems. Mutat Res 321:113-118.
13. Kakuda TM. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685-708.
14. Kirsch-Volders M, Elhajouji A, Cundari E, Van Hummelen P. 1997. The in vitro micronucleus test: A multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat Res 392:19-30.
15. Kuntz BA, Kohalmi SE, Kunkel TA, Mathews CK, McIntosh EM, Reidy JA. 1994. Deoxyribonucleoside triphosphate levels: A critical factor in the maintenance of genetic stability. Mutat Res 318:1-64.
16. Mace ML Jr, Daskal Y, Wray W. 1978. Scanning electron microscopy of chromosome aberrations. Mutat Res 52:199-206.
17. Meng Q, Olivero OA, Fasco MJ, Bellisario R, Kaminsky L, Pass KA, Wade N, Abrams E, Poirier MC, Walker VE, Protocol Team. 2007. Plasma and cellular markers of AZT metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs. Environ Mol Mutagen 48:307-321.
18. Mitelman F, editor. 1995. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger.
19. Norppa H, Falck GC-M. 2003. What do human micronuclei contain? Mutagenesis 18:221-233.
20. Olivero OA. 2007. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 48:215-223.
21. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. 1997. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89:1602-1608.
22. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Praia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC. 1999. Incorporation of zidovudine into leukocyte DNA from HIV-1 positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 13:919-925.
23. Paz-y-Miño C, Bustamante G, Sanchez ME, Leone PE. 2002. Cytogenetic monitoring in a population occupationally exposed to pesticides in Ecuador. Environ Health Perspect 110:1077-1080.
24. Perry P, Evans HJ. 1975. Cytological detection of mutagen-carcinogen exposure by sister chromatid exchange. Nature 258:121-125.
25. Perry PE, Thompson EJ. 1984. The methodology of sister chromatid exchanges. In: Kilbey BJ, Legator M, Nichols W, Ramel C, editors. Handbook of Mutagenicity Test Procedures, 2nd edition. Amsterdam: Elsevier Science Publishers, BV. p 495-529.
26. Physicians' Desk Reference. 2000. Healthcare Ser. 103 (online version). Micromedex.
27. Poirier MC, Olivero OA, Walker DM, Walker VE. 2004. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 199:151-161.
28. Rothfuss A, Schütz P, Bochum S, Volm T, Eberhardt E, Kreirenberg R, Vogel W, Speit G. 2000. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of BRCA1 mutation in breast cancer families. Cancer Res 60:390-394.
29. Schilling BE, Nelson DR, Proctor JE, Diamond SS, Kaul S, Hawkins HC. 1995. The nonclinical toxicologic profile of stavudine. Curr Ther Res 56:201-218.
30. Speit G, Haupter S. 1985. On the mechanisms of differential giemsa staining of bromodeoxyuridine-substituted chromosomes. II. Differences between THA demonstration of sister chromatid differentiation and replication patterns. Hum Genet 70:126-129.
31. Thust R, Schacke M, Wutzler P. 1996. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Antiviral Res 31:105-113.
32. Titenko-Holland N, Windham G, Kolachana P, Reinisch F, Parvatham S, Osorio AM, Smith MT. 1997. Genotoxicity of malathion in human lymphocytes assessed using the micronucleus assay in vitro and in vivo: A study of malathion-exposed workers. Mutat Res 388:85-95.
33. Torres SM, Walker DM, Carter MM, Cook DL Jr, McCash CL, Cordova EM, Olivero OA, Poirier MC, Walker VE. 2007. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. Environ Mol Mutagen 48:224-238.
34. +/- mice treated neonatally with zidovidine and lamivudine. Carcinogenesis 23:1427-1432.
35. Wutzler P, Thust R. 2001. Genetic risks of antiviral nucleoside analogues - a survey. Antiviral Res 49:55-74.